Literature DB >> 1902528

Gestational diabetes in a developing country, experience of screening at the Aga Khan University Medical Centre, Karachi.

K S Khan1, J H Rizvi, R N Qureshi, R Mazhar.   

Abstract

In order to determine the prevalence of glucose intolerance in pregnancy, 1267 consecutive women attending the antenatal clinic of the Aga Khan University Medical Centre were subjected to a 75 g glucose challenge followed 2 hr later by plasma glucose determination irrespective of gestation on the first antenatal visit. The test was repeated at 28-32 weeks of gestation if the patients had an abnormal initial screen at less than 28 weeks gestation and a normal glucose tolerance test on diagnostic follow-up and for those who had a risk factor for gestational diabetes and a normal initial screen at less than 28 weeks gestation. The glucose challenge test was abnormal (2 hr plasma glucose greater than 140 mg%) in 8.6% of the screened population. Follow-up oral glucose tolerance test on these patients revealed a prevalence of 3.2% of gestational diabetes and 1.9% of impaired glucose tolerance test based on the modified O'Sullivan criteria. Improvement in cost effectiveness of screening programmes was adjudged possible by avoiding glucose tolerance tests in patients with 2 hr plasma glucose value of greater than 170 mg% after a 75 g oral glucose challenge for screening.

Entities:  

Mesh:

Year:  1991        PMID: 1902528

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  2 in total

1.  KCNQ1 rs2237895 polymorphism is associated with Gestational Diabetes in Pakistani Women.

Authors:  Syeda Sadia Fatima; Bushra Chaudhry; Taseer Ahmed Khan; Saad Farooq
Journal:  Pak J Med Sci       Date:  2016 Nov-Dec       Impact factor: 1.088

Review 2.  The burden of diabetes mellitus during pregnancy in low- and middle-income countries: a systematic review.

Authors:  Lovney Kanguru; Navya Bezawada; Julia Hussein; Jacqueline Bell
Journal:  Glob Health Action       Date:  2014-07-01       Impact factor: 2.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.